The FDA has granted emergency use authorization for the Aptima Zika virus assay system, from Hologic, for detection of the...
Abbott announced that the U.S. FDA has authorised its molecular test, the Abbott RealTime ZIKA test, to detect Zika virus...
Luminex Corporation has received Emergency Use Authorization (EUA) from the FDA for a multiplex nucleic acid test called the xMAP...
Grifols announced that the FDA approved the Procleix Zika Virus assay for the detection of the virus in individual or...
Innovation Pharmaceuticals announced that brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.
Introduction: The REGAL (RSV Evidence - A Geographical Archive of the Literature) series has provided a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years.
Humanigen announced that the Brazilian regulatory agency, Anvisa, has granted permission to commence a Phase III study of lenzilumab in patients with COVID-19 in Brazil.
Objective: To investigate whether the incidence of dementia in the general population covaries with long-term exposure to microlevels of lithium in drinking water.
Respiratory syncytial virus associated acute lower respiratory infection (RSV-ALRI) constitutes a substantial disease burden in young children. We aimed to identify all studies investigating the risk factors of RSV-ALRI poor outcome or mortality in young children.
Background: Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infection globally. There are vaccine candidates in development, but a systematic review on immunogenicity and safety of vaccine is lacking.